Metastatic @entity263 is still commonly a lethal condition. The concept that ' @entity1 with @entity263 die with rather than of their @entity5 ' has been shown to be false. It is estimated that 10-20% of @entity1 in the UK present with locally @entity1442 . Median overall survival remains only 3.5 years for @entity1 presenting with @entity3 . The use of @entity4396 analogues to achieve medical castration has become the gold standard for both locally advanced @entity263 , combined with radiotherapy, and @entity3 . @entity342 deprivation therapy (ADT) is the standard first-line treatment for @entity1442 resulting in improvements in symptoms, radiological findings and PSA levels. Ultimately the majority of @entity1 with advanced @entity263 will develop resistance to ADT @entity1205 is the standard first-line therapy recommended by international guidelines for @entity1 with symptomatic metastatic castrate @entity263 who are suitable candidates for chemotherapy. More than 90% of @entity1 with castrate @entity263 have bone @entity3 . @entity44001 is a novel alpha-emitting radiopharmaceutical agent, which mimics calcium and therefore targets bone @entity3 . It is indicated in @entity1 with metastatic castrate @entity263 who have symptomatic bone @entity3 without visceral @entity3 .

New developments in XXXX therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity4396 :: ('2796', 'Gene') :: ['LHRH'] @entity263 :: ('MESH:D011471', 'Disease') :: ['refractory prostate cancer', 'prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['Androgen'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastatic disease'] @entity44001 :: ('CHEBI:74895', 'Chemical') :: ['Radium-223 dichloride'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel']
@entity263 :: (MESH:D011471,Disease) :: ['metastatic prostate cancer']
